Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply
Author:
Affiliation:
1. Carolina Urologic Research Center, Myrtle Beach, South Carolina
2. University of California, San Francisco
3. Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2798262/jamaoncology_shore_2022_lr_220024_1674054652.69422.pdf
Reference6 articles.
1. Active surveillance for low-risk prostate cancer: time trends and variation in the AUA Quality (AQUA) registry.;Cooperberg;J Urol,2022
2. Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial.;Shore;JAMA Oncol,2022
3. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.;Shore;Lancet Oncol,2016
4. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.;Armstrong;J Clin Oncol,2019
5. Serial molecular profiling of low-grade prostate cancer to assess tumor upgrading: a longitudinal cohort study.;Salami;Eur Urol,2021
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular Anatomy of Prostate Cancer and Its Implications in Active Surveillance and Early Intervention Strategies;Anatomia;2023-10-10
2. Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36;European Urology Open Science;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3